| __timestamp | Eli Lilly and Company | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 6620800000 | 7461000 |
| Thursday, January 1, 2015 | 6533000000 | 11960000 |
| Friday, January 1, 2016 | 6452000000 | 13108000 |
| Sunday, January 1, 2017 | 6588100000 | 17501000 |
| Monday, January 1, 2018 | 5975100000 | 22472000 |
| Tuesday, January 1, 2019 | 6213800000 | 24286000 |
| Wednesday, January 1, 2020 | 6121200000 | 29689000 |
| Friday, January 1, 2021 | 6431600000 | 38837000 |
| Saturday, January 1, 2022 | 6440400000 | 47489000 |
| Sunday, January 1, 2023 | 6941200000 | 53379000 |
| Monday, January 1, 2024 | 8593800000 |
Igniting the spark of knowledge
In the world of pharmaceuticals and biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability and growth. Eli Lilly and Company, a pharmaceutical giant, and Xencor, Inc., a biotechnology firm, present a fascinating contrast in their SG&A expenses from 2014 to 2023.
Eli Lilly's SG&A expenses have shown a steady trend, with a notable increase of approximately 5% from 2014 to 2023. This reflects the company's strategic investments in marketing and administration to support its expansive product portfolio. In contrast, Xencor, Inc., a smaller player, has seen its SG&A expenses grow by over 600% during the same period, indicating aggressive scaling and expansion efforts.
This comparison highlights the diverse strategies employed by companies in the sector, with larger firms focusing on stability and smaller ones on rapid growth.
Eli Lilly and Company and Vertex Pharmaceuticals Incorporated: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Eli Lilly and Company or Biogen Inc.
Eli Lilly and Company and Teva Pharmaceutical Industries Limited: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and United Therapeutics Corporation
Comparing SG&A Expenses: Eli Lilly and Company vs Madrigal Pharmaceuticals, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Apellis Pharmaceuticals, Inc.
Eli Lilly and Company vs ADMA Biologics, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Galapagos NV
Cost Management Insights: SG&A Expenses for Eli Lilly and Company and Evotec SE
Corcept Therapeutics Incorporated or Xencor, Inc.: Who Manages SG&A Costs Better?
ADMA Biologics, Inc. or Xencor, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Travere Therapeutics, Inc. and Xencor, Inc.